DAFNA Capital Management LLC Sells 10,000 Shares of Gossamer Bio, Inc. (NASDAQ:GOSS)

DAFNA Capital Management LLC reduced its position in Gossamer Bio, Inc. (NASDAQ:GOSS) by 0.7% in the fourth quarter, Holdings Channel.com reports. The firm owned 1,409,262 shares of the company’s stock after selling 10,000 shares during the quarter. DAFNA Capital Management LLC’s holdings in Gossamer Bio were worth $1,275,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of GOSS. Bank of America Corp DE lifted its holdings in shares of Gossamer Bio by 107.2% in the 4th quarter. Bank of America Corp DE now owns 84,788 shares of the company’s stock worth $77,000 after acquiring an additional 43,866 shares during the last quarter. Alyeska Investment Group L.P. raised its stake in shares of Gossamer Bio by 52.7% during the fourth quarter. Alyeska Investment Group L.P. now owns 8,808,514 shares of the company’s stock valued at $7,968,000 after acquiring an additional 3,041,058 shares during the last quarter. Allostery Investments LP purchased a new stake in Gossamer Bio in the 4th quarter worth approximately $555,000. Opti Capital Management LP bought a new stake in Gossamer Bio in the fourth quarter valued at $165,000. Finally, Silverarc Capital Management LLC increased its position in shares of Gossamer Bio by 9.3% during the fourth quarter. Silverarc Capital Management LLC now owns 6,171,847 shares of the company’s stock valued at $5,583,000 after buying an additional 526,495 shares during the period. 81.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

GOSS has been the subject of a number of research reports. Wedbush reiterated an “outperform” rating and issued a $4.00 price objective on shares of Gossamer Bio in a report on Friday, March 14th. The Goldman Sachs Group reduced their price objective on Gossamer Bio from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Thursday, April 17th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Gossamer Bio in a report on Tuesday, March 18th.

Gossamer Bio Trading Up 0.5 %

Gossamer Bio stock opened at $1.10 on Thursday. The business has a 50-day simple moving average of $1.06 and a two-hundred day simple moving average of $0.98. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 3.64. The company has a market cap of $248.81 million, a P/E ratio of -3.42 and a beta of 1.82. Gossamer Bio, Inc. has a 52-week low of $0.50 and a 52-week high of $1.55.

Gossamer Bio (NASDAQ:GOSS) last announced its quarterly earnings results on Tuesday, March 18th. The company reported ($0.15) EPS for the quarter, meeting analysts’ consensus estimates of ($0.15). The firm had revenue of $9.38 million for the quarter, compared to the consensus estimate of $7.02 million. Analysts predict that Gossamer Bio, Inc. will post -0.28 EPS for the current year.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.